Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers; Guidance for Industry; Availability; Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request
Published Date: 1/7/2025
Notice
Summary
The FDA just released final guidance on how companies can share scientific info about unapproved uses of approved medical products with health care providers. This update affects medical product firms and aims to clarify communication rules, but it won’t take effect until the Office of Management and Budget reviews the info collection by February 21, 2025. No new costs yet, but companies should get ready to follow these clearer, friendlier rules soon!
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
FDA reassurance on SIUU communications
The FDA issued final guidance (announced January 7, 2025) explaining its enforcement policy for firm-initiated scientific communications about unapproved uses of approved or cleared medical products to health care providers. The guidance says that if firms follow the recommendations in the guidance, FDA does not intend to use the firm's dissemination of such communications alone as evidence of a new intended use.
Required SIUU disclosures and paperwork burden
The guidance recommends specific disclosures firms should include when sharing scientific information on unapproved uses (SIUU communications) and FDA submitted the associated information collection for OMB review under control numbers 0910-0686 and 0910-0485. FDA estimates, for drug firms (OMB 0910-0686) 747 firms may each share 30 SIUU communications annually (2.5 hours per disclosure), totaling 129,231 disclosures and 56,249.1 hours per year; for device firms (OMB 0910-0485) 261 firms may each share 30 SIUU communications annually, totaling 45,153 disclosures and 19,653.3 hours per year.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Related Federal Register Documents
2026-20724, Notice of Intent To Prepare a Supplemental Environmental Impact Statement for the Sentinel Deployment and Minuteman III Decommissioning and Disposal
The Air Force is updating its plan to replace old Minuteman III missiles with new Sentinel missiles across five states, including Wyoming, Montana, and North Dakota. They’re checking how these changes might affect the environment and want your thoughts during a 30-day comment period starting now. This update could impact local lands and communities, with careful reviews to keep things safe and smart.
2026-20771, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the NIH is holding several closed virtual meetings in early November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers seeking funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-20708, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Amend the IEX Equities Fee Schedule
IEX is shaking up its fee schedule starting November 1, 2026, by tweaking who gets rebates for adding displayed liquidity and changing rebate amounts. This affects IEX members who trade stocks, giving them new ways to save or earn more on fees. The changes kick in right away after filing, so traders should get ready to adjust their strategies and cash flow.
2026-20710, Self-Regulatory Organizations; Investors Exchange LLC; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Pursuant to IEX Rule 15.110(a) and (c) To Modify the Required Criteria To Qualify for the Reduced Incremental Fee
Investors Exchange (IEX) is changing the rules for who can get a discount on certain trading fees. Starting November 1, 2026, members will need to meet new criteria to qualify for the reduced incremental fee, which could save or cost them money depending on their trading activity. This change affects all IEX members and kicks in right away to keep things fair and clear.
2026-20779, Passenger Vehicle and Light Truck Tires From Thailand: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
The U.S. Department of Commerce found that tires from Thailand were sold in the U.S. for less than their normal price between July 2024 and June 2025. This means some importers might have to pay extra duties to keep things fair. The review process had some delays due to government shutdowns, but now the preliminary results are out and open for comments.
2026-20763, National Environmental Policy Act Implementing Procedures: Wintertime Oil and Gas Exploration in the National Petroleum Reserve in Alaska Categorical Exclusion
Starting October 9, 2026, the Department of the Interior is making it easier and faster to approve wintertime oil and gas exploration in Alaska’s National Petroleum Reserve by adding a special rule that skips some usual paperwork. This change mainly affects energy companies working in the area and aims to speed up projects while still protecting the environment. No new costs are expected, but the process will be smoother and quicker.
Previous / Next Documents
Previous: 2024-31538, Recommendations To Reduce the Risk of Transmission of Disease Agents Associated With Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products; Guidance for Industry; Availability
The FDA just released new rules to help stop infections like sepsis from spreading through donated human cells and tissues. This affects all places that check donors before using their cells or tissues in treatments. These updated recommendations start right away and aim to keep patients safer without adding big costs or delays.
Next: 2024-31540, Pulse Oximeters for Medical Purposes-Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA is sharing draft rules to make sure pulse oximeters—those handy devices that check your blood oxygen and pulse—work well for everyone, no matter skin color. These new guidelines suggest how to test, label, and submit these devices for approval, aiming for safer and more accurate readings. Companies making these devices should check out the draft and send feedback by March 10, 2025, to help shape the final rules.